TY - JOUR
T1 - Operational lessons learned in conducting a multi-country collaboration for vaccine safety signal verification and hypothesis testing
T2 - The global vaccine safety multi country collaboration initiative
AU - Guillard-Maure, Christine
AU - Elango, Varalakshmi
AU - Black, Steven
AU - Perez-Vilar, Silvia
AU - Castro, Jose Luis
AU - Bravo-Alcántara, Pamela
AU - Molina-León, Helvert Felipe
AU - Weibel, Daniel
AU - Sturkenboom, Miriam
AU - Zuber, Patrick L.F.
N1 - Funding Information:
Center for Biologics Evaluation and Research (CBER)-U.S. Food and Drug Administration (FDA) funded this project. GRiP, Global Research in Pediatrics , European Union Seventh framework Programme (FP7/2007–2013) provided additional funding under grant agreement no. 261060 .
Publisher Copyright:
© 2017
PY - 2018/1/8
Y1 - 2018/1/8
N2 - Timely and effective evaluation of vaccine safety signals for newly developed vaccines introduced in low and middle- income countries (LMICs) is essential. The study tested the development of a global network of hospital-based sentinel sites for vaccine safety signal verification and hypothesis testing. Twenty-six sentinel sites in sixteen countries across all WHO regions participated, and 65% of the sites were from LMIC. We describe the process for the establishment and operationalization of such a network and the lessons learned in conducting a multi-country collaborative initiative. 24 out of the 26 sites successfully contributed data for the global analysis using standardised tools and procedures. Our study successfully confirmed the well-known risk estimates for the outcomes of interest. The main challenges faced by investigators were lack of adequate information in the medical records for case ascertainment and classification, and access to immunization data. The results suggest that sentinel hospitals intending to participate in vaccine safety studies strengthen their systems for discharge diagnosis coding, medical records and linkage to vaccination data. Our study confirms that a multi-country hospital-based network initiative for vaccine safety monitoring is feasible and demonstrates the validity and utility of large collaborative international studies to monitor the safety of new vaccines introduced in LMICs.
AB - Timely and effective evaluation of vaccine safety signals for newly developed vaccines introduced in low and middle- income countries (LMICs) is essential. The study tested the development of a global network of hospital-based sentinel sites for vaccine safety signal verification and hypothesis testing. Twenty-six sentinel sites in sixteen countries across all WHO regions participated, and 65% of the sites were from LMIC. We describe the process for the establishment and operationalization of such a network and the lessons learned in conducting a multi-country collaborative initiative. 24 out of the 26 sites successfully contributed data for the global analysis using standardised tools and procedures. Our study successfully confirmed the well-known risk estimates for the outcomes of interest. The main challenges faced by investigators were lack of adequate information in the medical records for case ascertainment and classification, and access to immunization data. The results suggest that sentinel hospitals intending to participate in vaccine safety studies strengthen their systems for discharge diagnosis coding, medical records and linkage to vaccination data. Our study confirms that a multi-country hospital-based network initiative for vaccine safety monitoring is feasible and demonstrates the validity and utility of large collaborative international studies to monitor the safety of new vaccines introduced in LMICs.
KW - Adverse events following immunization (AEFI)
KW - Global Vaccine Safety Initiative (GVSI)
KW - Post-marketing surveillance
KW - Vaccine safety
UR - http://www.scopus.com/inward/record.url?scp=85026632426&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2017.07.085
DO - 10.1016/j.vaccine.2017.07.085
M3 - Article
C2 - 28780118
AN - SCOPUS:85026632426
SN - 0264-410X
VL - 36
SP - 355
EP - 362
JO - Vaccine
JF - Vaccine
IS - 3
ER -